DE60136272D1 - Diagnostika und therapeutika für makula degeneration erkrankungen - Google Patents

Diagnostika und therapeutika für makula degeneration erkrankungen

Info

Publication number
DE60136272D1
DE60136272D1 DE60136272T DE60136272T DE60136272D1 DE 60136272 D1 DE60136272 D1 DE 60136272D1 DE 60136272 T DE60136272 T DE 60136272T DE 60136272 T DE60136272 T DE 60136272T DE 60136272 D1 DE60136272 D1 DE 60136272D1
Authority
DE
Germany
Prior art keywords
macular degeneration
therapeutics
diagnostics
degeneration diseases
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60136272T
Other languages
English (en)
Inventor
Gregory S Hageman
Robert F Mullins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation UIRF
Original Assignee
University of Iowa Research Foundation UIRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22742799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60136272(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Iowa Research Foundation UIRF filed Critical University of Iowa Research Foundation UIRF
Application granted granted Critical
Publication of DE60136272D1 publication Critical patent/DE60136272D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy
DE60136272T 2000-04-29 2001-04-30 Diagnostika und therapeutika für makula degeneration erkrankungen Expired - Lifetime DE60136272D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20069800P 2000-04-29 2000-04-29
PCT/US2001/013971 WO2001084149A2 (en) 2000-04-29 2001-04-30 Diagnostics and therapeutics for macular degeneration-related disorders

Publications (1)

Publication Number Publication Date
DE60136272D1 true DE60136272D1 (de) 2008-12-04

Family

ID=22742799

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60136272T Expired - Lifetime DE60136272D1 (de) 2000-04-29 2001-04-30 Diagnostika und therapeutika für makula degeneration erkrankungen

Country Status (10)

Country Link
US (5) US20020015957A1 (de)
EP (2) EP2026073B1 (de)
JP (1) JP4764590B2 (de)
AT (1) ATE412185T1 (de)
AU (2) AU6110301A (de)
CA (1) CA2407715C (de)
DE (1) DE60136272D1 (de)
DK (2) DK1287364T3 (de)
ES (1) ES2316446T3 (de)
WO (1) WO2001084149A2 (de)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7108982B1 (en) * 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
US20020102581A1 (en) * 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
US7011952B2 (en) * 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
WO2001084149A2 (en) * 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US6875165B2 (en) * 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
SE0100595D0 (sv) * 2001-02-22 2001-02-22 Lena Carlsson Immunological detection of prostate diseases and prostatic-related diseases
US6820011B2 (en) 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US8007804B2 (en) 2002-11-15 2011-08-30 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
JP4269064B2 (ja) * 2003-02-26 2009-05-27 国立大学法人 千葉大学 重症筋無力症の検査方法及びそのための検査薬
WO2004096277A1 (ja) * 2003-05-01 2004-11-11 Kyoto University 眼内血管新生疾患の予防又は治療剤
PL2374819T3 (pl) * 2003-05-12 2017-09-29 Helion Biotech Aps Przeciwciała przeciwko MASP-2
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
US7563222B2 (en) * 2004-02-12 2009-07-21 Neovista, Inc. Methods and apparatus for intraocular brachytherapy
WO2005079915A1 (en) * 2004-02-12 2005-09-01 Neo Vista, Inc. Methods and apparatus for intraocular brachytherapy
US20050250745A1 (en) * 2004-02-25 2005-11-10 Seddon Johanna M Biomarkers for age-related macular degeneration (AMD)
GB0412966D0 (en) * 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
PT2446900T (pt) * 2004-06-10 2017-06-28 Univ Leicester Métodos para tratar condições associadas com a ativação do complemento dependente de masp-2
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2005123776A1 (en) * 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with lectin-dependent complement activation
CA2513317A1 (en) 2004-07-06 2006-01-06 Kuhnil Pharmaceutical Co., Ltd. Composition for the diagnosis of retinal vascular disease comprising aldolase and method for diagnosis using it
WO2006042252A2 (en) 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
US8043609B2 (en) 2004-10-08 2011-10-25 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
US20090017029A1 (en) * 2004-11-18 2009-01-15 Yale University Methods and Compositions for Treating Ocular Disorders
CN103920142A (zh) * 2005-02-14 2014-07-16 爱荷华大学研究基金会 治疗和诊断年龄相关性黄斑变性的方法和试剂
WO2006096737A2 (en) * 2005-03-07 2006-09-14 The Trustees Of Boston University Diagnostic and therapeutic target for macular degeneration
US20090117171A1 (en) * 2005-03-11 2009-05-07 Cedric Francois Compositions and methods for treatment of macular degeneration and related conditions
ES2548700T3 (es) * 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas
EP1929037A4 (de) * 2005-08-24 2009-07-22 Cy O Connor Erade Village Foun Identifizierung angestammter haplotypen und verwendungen davon
US20080318264A1 (en) * 2005-09-09 2008-12-25 University Of Iowa Research Foundation Biomarkers Associated With Age-Related Macular Degeneration
EP1951279B1 (de) * 2005-10-08 2017-04-12 Apellis Pharmaceuticals, Inc. Compstatin und seine analoga zur behandlung von augenerkrankungen
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP3299027A1 (de) * 2005-11-04 2018-03-28 Genentech, Inc. Verwendung von komplementweginhibitoren zur behandlung von augenkrankheiten
AU2006315425A1 (en) * 2005-11-15 2007-05-24 Neovista Inc. Methods and apparatus for intraocular brachytherapy
KR20080087814A (ko) * 2005-12-22 2008-10-01 알콘 리서치, 리미티드 보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제
WO2007120975A2 (en) * 2006-02-13 2007-10-25 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Variants in complement regulatory genes predict age-related macular degeneration
US20080146501A1 (en) * 2006-02-13 2008-06-19 University Of Iowa Research Foundation Protective complement proteins and age-related macular degeneration
US8012683B2 (en) * 2006-02-13 2011-09-06 University Of Iowa Research Foundation Variants in complement regulatory genes predict age-related macular degeneration
RU2477137C2 (ru) * 2006-03-08 2013-03-10 АРКЕМИКС Эл Эл Си Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений
WO2007118095A2 (en) * 2006-04-03 2007-10-18 University Of Iowa Research Foundation Binding of complement factor h to c-reactive protein
WO2007149567A2 (en) 2006-06-21 2007-12-27 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
ATE551350T1 (de) 2006-07-13 2012-04-15 Univ Iowa Res Found Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration
WO2008024495A2 (en) * 2006-08-23 2008-02-28 University Of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
CA2939806A1 (en) * 2006-11-02 2008-05-08 Genentech, Inc. Humanized anti-factor d antibodies and uses thereof
WO2008091617A2 (en) * 2007-01-23 2008-07-31 Case Western Reserve University Method for detecting age related macular degeneration in a subject
HUE026001T2 (en) 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
US7972787B2 (en) 2007-02-16 2011-07-05 Massachusetts Eye And Ear Infirmary Methods for detecting age-related macular degeneration
AU2008221287A1 (en) * 2007-03-01 2008-09-04 Wellstat Immunotherapeutics, Llc Treatment of diseases characterized by inflammation
ES2507542T3 (es) 2007-03-14 2014-10-15 Alexion Cambridge Corporation Anticuerpo anti-factor B humanizado
US20100015139A1 (en) * 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
AU2008248043A1 (en) * 2007-04-30 2008-11-13 Alcon Research, Ltd. Treatment of age-related macular degeneration using inhibitors of complement factor D
WO2009029784A1 (en) * 2007-08-29 2009-03-05 Novelmed Therapeutics, Inc. Inhibition of complement and cellular activation
AU2015202046B2 (en) * 2008-02-15 2017-06-29 Tufts University A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
PL2252317T3 (pl) * 2008-02-15 2014-09-30 Univ Tufts Leczenie zwyrodnienia plamki żółtej
US8114592B2 (en) 2008-03-18 2012-02-14 Cambridge Enterprise Limited Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
AU2009256236A1 (en) 2008-06-04 2009-12-10 Neovista, Inc. Handheld radiation delivery system for advancing a radiation source wire
EP2815766B1 (de) 2008-08-05 2017-07-05 Novartis AG Zusammensetzungen und Verfahren für auf das Komplementprotein C5 gerichtete Antikörper
GB0816702D0 (en) * 2008-09-12 2008-10-22 Trinity College Dublin Complement proteins
WO2010129351A1 (en) * 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
WO2011006161A2 (en) 2009-07-10 2011-01-13 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating macular degeneration
WO2011017229A2 (en) * 2009-08-06 2011-02-10 Tufts - New England Medical Center Plasma complement components as expression markers for age-related macular degeneration and related phenotypes
MX354028B (es) * 2009-10-16 2018-02-08 Omeros Corp Uso de una composición que comprende un agente inhibidor de masp-2 efectivo para inhibir o prevenir la aparición de agregados en la vasculatura de un sujeto que sufre de un desorden de coagulación mediado por complemento.
WO2011053774A1 (en) 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
WO2011057158A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
AU2011241402B2 (en) * 2010-04-13 2016-09-15 M-Lab Gmbh Diagnostic methods for glaucoma
US9650447B2 (en) 2010-05-14 2017-05-16 The Regents Of The University Of Colorado, A Body Corporate Complement receptor 2 (CR2) targeting groups
JP2013533243A (ja) 2010-06-22 2013-08-22 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 補体成分３のＣ３ｄ断片に対する抗体
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
CA2843684A1 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
WO2012040619A2 (en) 2010-09-24 2012-03-29 Massachusetts Eye And Ear Infirmary Methods and compositions for prognosing and/or detecting age-related macular degeneration
AU2011336702B2 (en) 2010-11-29 2016-10-06 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
KR101256908B1 (ko) 2011-04-28 2013-04-23 (주)에이치비메디컬스 주름제거용 충전체
BR112014015111A2 (pt) 2011-12-21 2017-06-13 Novartis Ag composições e processos para anticorpos que se direcionam ao fator p
WO2013163758A1 (en) * 2012-05-01 2013-11-07 Boyd Shelley Romayne Methods for treating and diagnosing blinding eye diseases
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
WO2014028861A1 (en) 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
DK2920201T3 (da) 2012-11-15 2020-04-14 Apellis Pharmaceuticals Inc Langtidsvirkende compstatin-analoger og relaterede sammensætninger og fremgangsmåder
CA2906527A1 (en) 2013-03-14 2014-09-25 Baxalta Incorporated Factor h for transplantation
US9248162B2 (en) 2013-03-14 2016-02-02 Baxalta Incorporated Factor H for treatment of rheumatoid arthritis
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
JP6463359B2 (ja) 2013-08-12 2019-01-30 ジェネンテック， インコーポレイテッド 補体関連病態を治療するための組成物及び方法
AU2015223056B2 (en) 2014-02-27 2020-10-01 Allergan, Inc. Complement Factor Bb antibodies
WO2015168468A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
JP6663441B2 (ja) 2015-03-01 2020-03-11 ノバサイト リミテッド 眼球運動を測定するためのシステム
EP3115784A1 (de) * 2015-07-10 2017-01-11 Koss, Michael Janusz Polypeptidmarker zur analyse, diagnose und therapie von augenbezogenen erkrankungen
EP3359555B1 (de) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosierpläne
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
US20190049465A1 (en) * 2016-02-06 2019-02-14 Georgetown University Compositions and methods for the diagnosis and treatment of age-related macular degeneration
CN109219386B (zh) 2016-05-29 2021-06-22 诺瓦赛特有限公司 显示系统和方法
WO2018055618A1 (en) 2016-09-23 2018-03-29 Novasight Ltd. Screening apparatus and method
JP7173965B2 (ja) * 2016-10-19 2022-11-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 試料中の非結合Ｃ５ａの定量化方法
BR112019020955A2 (pt) 2017-04-07 2020-05-05 Apellis Pharmaceuticals Inc regimes de dosagem e composições e métodos relacionados
WO2019006153A1 (en) * 2017-06-30 2019-01-03 Anthrobio IMPROVEMENT OF THE PROTEOLYTIC CASCADE FOR THE TREATMENT OF A DISEASE
EP3655545B1 (de) 2017-07-18 2023-10-18 The Research Foundation for The State University of New York Biomarker für intrakranielles aneurysma
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
CA3145870A1 (en) * 2019-07-26 2021-02-04 Hampar L. Karageozian Peptides for treating non-exudative macular degeneration and other disorders of the eye

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US102581A (en) * 1870-05-03 Improvement in boiler-furnaces
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3650090A (en) * 1970-06-19 1972-03-21 Phillips Petroleum Co Analysis of gaseous mixtures
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5256642A (en) 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5506247A (en) 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
GB8912497D0 (en) 1989-05-31 1989-07-19 Cobbold Stephen P Monoclonal antibodies
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH05507700A (ja) 1990-06-01 1993-11-04 カイロン　コーポレイション 生物学的活性分子を同定するための組成物及び方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP2001524926A (ja) 1991-09-18 2001-12-04 アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ オリゴマーの雑多ライブラリーの集合体を合成する方法
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IL107166A (en) 1992-10-01 2000-10-31 Univ Columbia Complex combinatorial chemical libraries encoded with tags
US5547835A (en) 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
WO1994017822A1 (en) 1993-02-12 1994-08-18 T Cell Sciences, Inc. PULMONARY ADMINISTRATION OF sCR1 AND OTHER COMPLEMENT INHIBITORY PROTEINS
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5583973A (en) 1993-09-17 1996-12-10 Trustees Of Boston University Molecular modeling method and system
US6153203A (en) 1993-10-08 2000-11-28 Duotol Ab Immunological tolerance-inducing agent
US5681571A (en) 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
AU703472B2 (en) 1993-11-02 1999-03-25 Affymax Technologies N.V. Synthesizing and screening molecular diversity
AU1441395A (en) * 1993-12-21 1995-07-10 St. Louis University Ocular diagnostics and therapies
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JPH10500112A (ja) 1994-05-06 1998-01-06 ファーマコピーア，インコーポレイテッド 組合せ ジヒドロベンゾピラン ライブラリー
GB2290293A (en) 1994-06-08 1995-12-20 Rupert Donald Holms Preparation which inhibits the autoimmune response in HIV, or SLE, patients
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US5612894A (en) 1995-02-08 1997-03-18 Wertz; David H. System and method for molecular modeling utilizing a sensitivity factor
US6103235A (en) 1995-10-30 2000-08-15 The United States Of America As Represented By The Department Of Health And Human Services Methods of inducing immune tolerance using immunotoxins
JPH09194393A (ja) 1996-01-22 1997-07-29 Meiji Milk Prod Co Ltd 免疫寛容を誘導する方法、免疫寛容誘導食品キットおよび免疫寛容誘導剤キット
EP0888459A1 (de) 1996-02-02 1999-01-07 Stichting Onderzoeksbeleid Cardiopulmonale Chirurgie Messung der komplementaktivierung durch biomaterialien mittels komplementkonvertase-spaltung von peptidesubstraten
PL187733B1 (pl) 1996-02-26 2004-09-30 Advanced Res & Tech Inst Zastosowanie inhibitora anhydrazy węglanowej
US5843449A (en) 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5686598A (en) 1996-08-22 1997-11-11 The Jackson Laboratory Genes associated with retinal dystrophies
JP2000509255A (ja) 1996-04-10 2000-07-25 アキシーズ ファーマシューティカルズ インク． 感覚神経障害と関連した遺伝子ファミリー
US5705380A (en) 1996-09-04 1998-01-06 Sequana Theraputics, Inc. Identification of a gene encoding TULP2, a retina specific protein
US6102236A (en) * 1997-01-31 2000-08-15 Tetra Laval Holdings & Finance S.A. Lid of a container for beverages
US5773673A (en) * 1997-07-01 1998-06-30 Occidental Chemical Corporation Method of making chlorinated hydrocarbons
ATE291097T1 (de) 1997-10-31 2005-04-15 Affymetrix Inc A Delaware Corp Expressionsprofile in adulten und fötalen organen
US6956107B2 (en) * 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US7108982B1 (en) * 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
US20030149997A1 (en) 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
WO2000052479A2 (en) 1999-03-05 2000-09-08 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
WO2001084149A2 (en) 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
CA2939806A1 (en) * 2006-11-02 2008-05-08 Genentech, Inc. Humanized anti-factor d antibodies and uses thereof
AU2008251801A1 (en) * 2007-05-11 2008-11-20 The General Hospital Corporation Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento

Also Published As

Publication number Publication date
DK2026073T3 (en) 2016-07-25
AU2001261103B2 (en) 2007-08-23
EP2026073B1 (de) 2016-03-30
CA2407715C (en) 2009-03-24
EP1287364B1 (de) 2008-10-22
JP2003535581A (ja) 2003-12-02
EP2026073A1 (de) 2009-02-18
US20110182908A1 (en) 2011-07-28
WO2001084149A2 (en) 2001-11-08
US20030207309A1 (en) 2003-11-06
JP4764590B2 (ja) 2011-09-07
AU6110301A (en) 2001-11-12
US20180335436A1 (en) 2018-11-22
EP1287364A2 (de) 2003-03-05
US20020015957A1 (en) 2002-02-07
ES2316446T3 (es) 2009-04-16
CA2407715A1 (en) 2001-11-08
US20060263819A1 (en) 2006-11-23
DK1287364T3 (da) 2009-03-02
WO2001084149A3 (en) 2002-07-18
US7351524B2 (en) 2008-04-01
ATE412185T1 (de) 2008-11-15

Similar Documents

Publication Publication Date Title
DE60136272D1 (de) Diagnostika und therapeutika für makula degeneration erkrankungen
WO2003071927A3 (en) Diagnostics and therapeutics for macular degeneration-related disorders
DE60040150D1 (de) Diagnostika für fragile plaque störung
ATE343792T1 (de) Diagnostika und therapeutika für maculare degeneration
DE602006008456D1 (de) Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen
DE60226036D1 (de) ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
HK1069767A1 (en) Methods for inhibiting ocular processes
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DK1613347T3 (da) Humaniserede antistoffer, der genkender beta-amyloidpeptid
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
DE602006009652D1 (de) Eine herstellungsmethode von entacapon-enthaltenden granulaten für orale dosierformen
WO2005037203A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
TW200709817A (en) Platform antibody compositions
NO20055415L (no) Humaniserte antistoffer som gjenkjenner beta-amyloidpeptid
NO20035474D0 (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
NO20033821D0 (no) Anvendelse av GABA A inverse agonister i kombinasjon med nikotinreseptordelagonister, östrogen, selektive östrogenmodulatorer, ellervitamin E for behandling av kognitive forstyrrelser
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
WO2005014814A3 (en) 5’-and 3’-capped aptamers and uses therefor
DE60125681D1 (de) Verwendung von NMDA NR2B Antagonist zur Behandlung von Depressionen.
WO2005044200A3 (en) Methods and compositions for treating mcp-1 related pathologies
WO2000052479A3 (en) Diagnostics and therapeutics for drusen associated ocular disorders
EP1558766A4 (de) Verwendung von a33-antigenen und jam-it
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
TW200637545A (en) Novel uses for estrogen beta agonists
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression

Legal Events

Date Code Title Description
8364 No opposition during term of opposition